Schroder Investment Management Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.74M | Sell |
16,253
-55,458
| -77% | -$8.23M | ﹤0.01% | 869 |
|
|
2026
Q1 | $9.45M | Sell |
71,711
-15,315
| -18% | -$2.03M | 0.01% | 680 |
|
|
2025
Q4 | $12.3M | Buy |
87,026
+84,225
| +3,007% | +$12.2M | 0.01% | 602 |
|
|
2025
Q3 | $393K | Sell |
2,801
-26,131
| -90% | -$3.54M | ﹤0.01% | 1108 |
|
|
2025
Q2 | $3.64M | Sell |
28,932
-803
| -3% | -$92.1K | ﹤0.01% | 826 |
|
|
2025
Q1 | $3.29M | Sell |
29,735
-97,000
| -77% | -$12.3M | ﹤0.01% | 836 |
|
|
2024
Q4 | $17.3M | Sell |
126,735
-84,539
| -40% | -$10.5M | 0.02% | 539 |
|
|
2024
Q3 | $24.3M | Buy |
211,274
+25,890
| +14% | +$3.55M | 0.02% | 464 |
|
|
2024
Q2 | $25.5M | Buy |
185,384
+35,257
| +23% | +$4.84M | 0.03% | 426 |
|
|
2024
Q1 | $20.7M | Buy |
150,127
+74,592
| +99% | +$10.2M | 0.02% | 485 |
|
|
2023
Q4 | $9.95M | Buy |
75,535
+17,931
| +31% | +$2.06M | 0.01% | 634 |
|
|
2023
Q3 | $6.48M | Sell |
57,604
-5,689
| -9% | -$599K | 0.01% | 688 |
|
|
2023
Q2 | $5.97M | Buy |
63,293
+7,451
| +13% | +$728K | 0.01% | 744 |
|
|
2023
Q1 | $5.65M | Buy |
55,842
+48,729
| +685% | +$5.07M | 0.01% | 753 |
|
|
2022
Q4 | $850K | Sell |
7,113
-3,319
| -32% | -$389K | ﹤0.01% | 1069 |
|
|
2022
Q3 | $1.11M | Buy |
+10,432
| New | +$1.06M | ﹤0.01% | 1037 |
|
|
2019
Q4 | – | Sell |
-3,180
| Closed | -$287K | – | 1325 |
|
|
2019
Q3 | $287K | Buy |
3,180
+278
| +10% | +$26K | ﹤0.01% | 1118 |
|
|
2019
Q2 | $245K | Sell |
2,902
-11,274
| -80% | -$926K | ﹤0.01% | 1066 |
|
|
2019
Q1 | $1.25M | Buy |
14,176
+5,440
| +62% | +$455K | ﹤0.01% | 859 |
|
|
2018
Q4 | $624 | Sell |
8,736
-10,214
| -54% | -$979K | ﹤0.01% | 964 |
|
|
2018
Q3 | $2.33M | Sell |
18,950
-5,549
| -23% | -$630K | ﹤0.01% | 798 |
|
|
2018
Q2 | $2.38M | Hold |
24,499
| – | – | ﹤0.01% | 815 |
|
|
2018
Q1 | $2.03M | Sell |
24,499
-4,477
| -15% | -$378K | ﹤0.01% | 861 |
|
|
2017
Q4 | $2.25M | Sell |
28,976
-8,129
| -22% | -$554K | ﹤0.01% | 880 |
|
|
2017
Q3 | $2.2M | Buy |
37,105
+16,609
| +81% | +$876K | ﹤0.01% | 873 |
|
|
2017
Q2 | $948K | Hold |
20,496
| – | – | ﹤0.01% | 976 |
|
|
2017
Q1 | $856K | Buy |
20,496
+335
| +2% | +$14.4K | ﹤0.01% | 974 |
|
|
2016
Q4 | $780K | Sell |
20,161
-7,046
| -26% | -$319K | ﹤0.01% | 940 |
|
|
2016
Q3 | $1.38M | Sell |
27,207
-18,082
| -40% | -$901K | ﹤0.01% | 873 |
|
|
2016
Q2 | $2.06M | Buy |
+45,289
| New | +$2.09M | ﹤0.01% | 833 |
|
|
2013
Q4 | – | Sell |
-44,507
| Closed | -$504K | – | 1534 |
|
|
2013
Q3 | $504K | Buy |
+44,507
| New | +$612K | ﹤0.01% | 1096 |
|
Other funds holding NBIX
Schroder Investment Management Group's NBIX Position: Q2 2026 in Review
Schroder Investment Management Group reduced its Neurocrine Biosciences (NBIX) stake by 77% in Q2 2026, selling an estimated $8.23M and leaving 16,253 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #869.
Schroder Investment Management Group first reported a position in NBIX in Q3 2013 and has held it in 31 quarters since. The position peaked at $25.5M in Q2 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Schroder Investment Management Group held 16,253 shares of Neurocrine Biosciences worth $2.74M as of Q2 2026.
- Schroder Investment Management Group sold 55,458 Neurocrine Biosciences shares in Q2 2026, an estimated $8.23M.
- Neurocrine Biosciences made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #869 holding.
- Schroder Investment Management Group first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 31 quarters since.
- Schroder Investment Management Group's Neurocrine Biosciences position peaked at $25.5M in Q2 2024.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.